Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-04-01 @ 3:12 AM
Study NCT ID:
NCT06529250
Status:
RECRUITING
Last Update Posted:
2025-01-16
First Post:
2024-07-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IIT2023005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None